Try GOLD - Free
High Growth Health Insurance Market Still Remains Underpenetrated
Bio Spectrum
|February 2018 ,Vol 16 Issue 05
India’s healthcare industry is one of the fastest growing sectors and in the coming 10 years it is expected to reach $275 billion. Indian healthcare sector is much diversified and is full of opportunities in every segment which includes providers, payers and medical technology. With the increase in the competition, businesses are looking to explore for the latest dynamics and trends which will have positive impact on their business.
Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.
Indian healthcare delivery system is categorised into two major components - public and private. The Government, i.e. public healthcare system comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of primary healthcare centres (PHCs) in rural areas. The private sector provides majority of secondary, tertiary and quaternary care institutions with a major concentration in metros, tier I and tier II cities.
The healthcare sector in India is largely underpenetrated with government expenditure constituting approximately 1.4 per cent of India’s GDP. Private sector expenditure constitutes 70 per cent of the total healthcare expenditure out of which 62 per cent is out of pocket while only 8 per cent is covered through pre-financed instruments, as per World Bank Data (2014). Moreover, less than 30 per cent of India’s population has healthcare cover indicating considerable potential for the health insurance industry.
The health insurance industry, as of today, caters largely to institutional treatment, leading to considerable opportunities in targeting outpatient treatment in areas such as consultation fees, diagnostics and medicine expenses. The outpatient treatment, with medical inflation at ~15 per cent has created a strong need of developing a health savings account product combined with a robust health insurance plan in order to bring in spend efficiencies and protection for the Indian population.
This story is from the February 2018 ,Vol 16 Issue 05 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
India's Strategic Shift Towards High-Quality, Low-Cost MedTech
India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.
4 mins
December 2025
Bio Spectrum
How India's Diabetes Crisis is Driving Med Devices Market
A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.
9 mins
December 2025
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Translate
Change font size
